For RA Elders, Is There a Better Target Than TNF? medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Javascript needed
Please enable JavaScript on your browser, so that you can use all features of this website.« Back to the search result listmain-content
Top
Salt intake may be linked to disease activity, hypertension in RA
medwireNews: Urinary sodium-to-potassium (Na/K) ratio is independently and positively associated with disease activity and hypertension in people with rheumatoid arthritis (RA), Japanese study findings indicate.
This suggests that “dietary modifications such as salt restriction and potassium supplementation should be investigated as a potential candidate for attenuating both disease activity and hypertension in RA patients,” write Hiroto Minamino, from Kyoto University, and colleagues in
Vasculitis Rates Rise With Earth s Latitude medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Medically Reviewed
If your psoriatic arthritis medication isn’t working, your doctor may up the dose, try a different drug of the same type, or switch to an entirely different drug class.
Everyday Health
When you’re newly diagnosed with psoriatic arthritis and prescribed medication, know there’s a good chance your treatment plan may need to change before too long.
The first few months after a psoriatic arthritis diagnosis can be tricky as you and your doctor figure out which medications are most effective for you. It’s often a trial-and-error process that may involve starting a new medication or adding one to your treatment regimen.
Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.